Evaluation of the effect of treatment of latent tuberculosis infection on QuantiFERON-TB gold assay results.
To evaluate the utility of the QuantiFERON-TB Gold assay for monitoring latent tuberculosis treatment efficacy, the assay was performed serially for healthcare workers receiving isoniazid therapy. After 9 months of isoniazid therapy, all of these healthcare workers remained QuantiFERON-TB Gold positive, and cellular proliferation assays revealed persistently strong purified protein derivative responses. These results do not support the use of the QuantiFERON-TB Gold assay to monitor therapy.
Pollock
Nira R
NR
Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts 12215, USA. npollock@bidmc.harvard.edu
Kashino
Suely S
SS
Napolitano
Danielle R
DR
Sloutsky
Alex
A
Joshi
Swati
S
Guillet
Jasmine
J
Wong
Michael
M
Nardell
Edward
E
Campos-Neto
Antonio
A
D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000097:blood*; D007538:Isoniazid / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D011933:Reagent Kits, Diagnostic; D012882:Skin Tests; D016896:Treatment Outcome; D014373:Tuberculin / Q000276:immunology; D014376:Tuberculosis / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology
D000995:Antitubercular Agents; D011933:Reagent Kits, Diagnostic; D014373:Tuberculin; D007371:Interferon-gamma; D007538:Isoniazid